Inosine: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Protected "Inosine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(No difference)

Revision as of 19:15, 27 September 2011

Inosine
Clinical data
ATC code
Pharmacokinetic data
MetabolismHepatic
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC10H12N4O5
Molar mass268.229 g/mol

WikiDoc Resources for Inosine

Articles

Most recent articles on Inosine

Most cited articles on Inosine

Review articles on Inosine

Articles on Inosine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Inosine

Images of Inosine

Photos of Inosine

Podcasts & MP3s on Inosine

Videos on Inosine

Evidence Based Medicine

Cochrane Collaboration on Inosine

Bandolier on Inosine

TRIP on Inosine

Clinical Trials

Ongoing Trials on Inosine at Clinical Trials.gov

Trial results on Inosine

Clinical Trials on Inosine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Inosine

NICE Guidance on Inosine

NHS PRODIGY Guidance

FDA on Inosine

CDC on Inosine

Books

Books on Inosine

News

Inosine in the news

Be alerted to news on Inosine

News trends on Inosine

Commentary

Blogs on Inosine

Definitions

Definitions of Inosine

Patient Resources / Community

Patient resources on Inosine

Discussion groups on Inosine

Patient Handouts on Inosine

Directions to Hospitals Treating Inosine

Risk calculators and risk factors for Inosine

Healthcare Provider Resources

Symptoms of Inosine

Causes & Risk Factors for Inosine

Diagnostic studies for Inosine

Treatment of Inosine

Continuing Medical Education (CME)

CME Programs on Inosine

International

Inosine en Espanol

Inosine en Francais

Business

Inosine in the Marketplace

Patents on Inosine

Experimental / Informatics

List of terms related to Inosine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Inosine is a nucleoside that is formed when hypoxanthine is attached to a ribose ring (also known as a ribofuranose) via a β-N9-glycosidic bond.

Inosine is commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs.

Knowledge of inosine metabolism has led to advances in immunotherapy in recent decades. Inosine monophosphate is oxidised by the enzyme inosine monophosphate dehydrogenase yielding xanthosine monophosphate, a key precursor in purine metabolism. Mycophenolate mofetil is an anti-metabolite, anti-proliferative drug, used in the treatment of a variety of autoimmune diseases including Wegener's granulomatosis. The uptake of purine by actively dividing B cells can exceed 8 times that of normal body cells and therefore this set of white cells (which cannot operate purine salvage pathways) is selectively targeted by the purine deficiency resulting from IMD inhibition.

Reactions

Adenine is converted to adenosine or IMP, either of which in turn is converted into inosine (I), which pairs with adenine (A), cytosine (C) and uracil (U).

Purine nucleoside phosphorylase intraconverts inosine and hypoxanthine.

Inosine is also an intermediate in a chain of purine nucleotides reactions required for muscle movements.

Clinical significance

It was tried in the seventies in eastern countries for improving athletic performance, based on the fact that is an intermediate compound used in the muscle movements. Nevertheless the clinical trials with this purpose showed no improvement.[1]

Nowadays, it has been shown that inosine has neuroprotective properties. It has been proposed for administration after stroke, because observation has shown that axonal re-wiring is encouraged.[2] It has been tried also for multiple sclerosis and is currently in phase II of the trials [2].

It produces uric acid after ingestion, which is a natural antioxidant and a peroxinitrite scavenger, which can explain the behaviour in multiple sclerosis [3](peroxynitrite has been correlated with the axons degeneration [4]).

Currently Boston Life Sciences holds the patent for treatment of stroke [5] and this company is currently investigating its properties for MS under the name axosine for Multiple Sclerosis.

Biotechnology

When designing primers for polymerase chain reaction, inosine is useful in that it will indiscriminately pair with adenine, thymine, or cytosine. This allows one to design a primer that spans a single nucleotide polymorphism, without worry that the polymorphism will disrupt the primer's annealing efficiency.

References

  1. McNaughton L, Dalton B, Tarr J (1999). "Inosine supplementation has no effect on aerobic or anaerobic cycling performance". International journal of sport nutrition. 9 (4): 333–44. PMID 10660865.
  2. Chen P, Goldberg DE, Kolb B, Lanser M, Benowitz LI (2002). "Inosine induces axonal rewiring and improves behavioral outcome after stroke". Proc. Natl. Acad. Sci. U.S.A. 99 (13): 9031–6. doi:10.1073/pnas.132076299. PMID 12084941.

External links

Template:SIB de:Inosin

Template:WH Template:WikiDoc Sources